Trials / Active Not Recruiting
Active Not RecruitingNCT02042807
To Evaluate the Effect of MCS® in Prostate Cancer Prevention
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 702 (estimated)
- Sponsor
- Health Ever Bio-Tech Co., Ltd. · Industry
- Sex
- Male
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | MCS® |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2014-01-23
- Last updated
- 2024-06-13
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02042807. Inclusion in this directory is not an endorsement.